EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Gert Luurtsema; Verena Pichler; Salvatore Bongarzone; Yann Seimbille; Philip Elsinga; Antony Gee; Johnny Vercouillie

doi:10.1186/s41181-021-00149-6

EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Gert Luurtsema
, Verena Pichler
, Salvatore Bongarzone
, Yann Seimbille
, Philip Elsinga
, Antony Gee
, Johnny Vercouillie

Department of Pharmaceutical Sciences

Publications: Contribution to journal › Article › Peer Reviewed

Original language	English
Article number	34
Number of pages	16
Journal	EJNMMI Radiopharmacy and Chemistry
Volume	6
Issue number	1
DOIs	https://doi.org/10.1186/s41181-021-00149-6
Publication status	Published - 9 Oct 2021

Funding

We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Austrian Fields of Science 2012

104020 Radiochemistry

Keywords

Carrier
Mass
Molar activity (A)
Radioactivity
Radiochemistry
Specific activity (A)
Standardisation
Tracers
P-GLYCOPROTEIN FUNCTION
LIVING HUMAN-BRAIN
BLOOD-BRAIN-BARRIER
QUANTITATIVE-ANALYSIS
Molar activity (A(m))
Specific activity (A(s))
TRACER
IN-VIVO
AUTOMATED SYNTHESIS
C-11 RACLOPRIDE
BINDING
PET

Access to Document

10.1186/s41181-021-00149-6

Cite this

@article{cbf1a4b28c5a43479620090b014b8f97,

title = "EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality",

keywords = "Carrier, Mass, Molar activity (A), Radioactivity, Radiochemistry, Specific activity (A), Standardisation, Tracers, P-GLYCOPROTEIN FUNCTION, LIVING HUMAN-BRAIN, BLOOD-BRAIN-BARRIER, QUANTITATIVE-ANALYSIS, Molar activity (A(m)), Specific activity (A(s)), TRACER, IN-VIVO, AUTOMATED SYNTHESIS, C-11 RACLOPRIDE, BINDING, PET",

author = "Gert Luurtsema and Verena Pichler and Salvatore Bongarzone and Yann Seimbille and Philip Elsinga and Antony Gee and Johnny Vercouillie",

note = "Funding Information: We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes. Publisher Copyright: {\textcopyright} 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = oct,

day = "9",

doi = "10.1186/s41181-021-00149-6",

language = "English",

volume = "6",

journal = "EJNMMI Radiopharmacy and Chemistry",

issn = "2365-421X",

publisher = "Springer International Publishing",

number = "1",

}

TY - JOUR

T1 - EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals

T2 - impact on safety and imaging quality

AU - Luurtsema, Gert

AU - Pichler, Verena

AU - Bongarzone, Salvatore

AU - Seimbille, Yann

AU - Elsinga, Philip

AU - Gee, Antony

AU - Vercouillie, Johnny

N1 - Funding Information: We thank the EANM committees, EANM national delegates for their review, suggestions and comments. The authors (G.L. and P.E.) thank Prof. dr. A.D. Windhorst for sharing his expertise on Am. Preamble : The European Association of Nuclear Medicine (EANM) is a professional non-profit medical association that facilitates communication worldwide among individuals pursuing clinical and research excellence in nuclear medicine. The EANM was founded in 1985. This EANM guideline has been written by members who are selected on the basis of their scientific good standing and active engagement with relevant scientific societies. This guideline is intended to assist professionals to correctly define and measure molar activity (Am) and specific activity (As), discuss common pitfalls and good practice in the production and measurement of radiotracers with high Am and is written in accordance with the recently published consensus nomenclature rules (Coenen et al. 2017). Scope : Several classes of compounds such as small molecules, peptides and macromolecules radiolabelled for diagnostic and therapeutic purposes. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/10/9

Y1 - 2021/10/9

KW - Carrier

KW - Mass

KW - Molar activity (A)

KW - Radioactivity

KW - Radiochemistry

KW - Specific activity (A)

KW - Standardisation

KW - Tracers

KW - P-GLYCOPROTEIN FUNCTION

KW - LIVING HUMAN-BRAIN

KW - BLOOD-BRAIN-BARRIER

KW - QUANTITATIVE-ANALYSIS

KW - Molar activity (A(m))

KW - Specific activity (A(s))

KW - TRACER

KW - IN-VIVO

KW - AUTOMATED SYNTHESIS

KW - C-11 RACLOPRIDE

KW - BINDING

KW - PET

UR - https://www.scopus.com/pages/publications/85116846264

U2 - 10.1186/s41181-021-00149-6

DO - 10.1186/s41181-021-00149-6

M3 - Article

AN - SCOPUS:85116846264

SN - 2365-421X

VL - 6

JO - EJNMMI Radiopharmacy and Chemistry

JF - EJNMMI Radiopharmacy and Chemistry

IS - 1

M1 - 34

ER -

EANM guideline for harmonisation on molar activity or specific activity of radiopharmaceuticals: impact on safety and imaging quality

Funding

UN SDGs

Austrian Fields of Science 2012

Keywords

Access to Document

Other files and links

Fingerprint

Cite this